Bicycle Therapeutics Investor Presentation • January 2026 Forward-looking statements This presentation may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts", "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that a ...

ADMA Biologics Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology January 2026 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, "we," "our" or the "Company"), including, without limitation, statements that may predict, forecast, indicate, or imply future results, performan ...

January 9, 2026 Zanidatamab: Pivotal Phase 3 HERIZON-GEA-01 Trial Results in Gastroesophageal Adenocarcinoma (GEA) Innovating to Transform the Lives of Patients and Their Families Intended for U.S. investor audiences only. Intended for U.S. investor audiences only. 2 January 9, 2026 Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the C ...

KalVista Pharmaceuticals Corporate Overview January 2026 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be ...

Financial Performance and Targets - Yara aims for a through-the-cycle Return on Invested Capital (ROIC) exceeding 10%[29] - The company has already delivered >180 MUSD EBITDA increase and is committed to further cash flow improvement[26] - Yara targets >350 MUSD EBITDA improvement and >600 MUSD sustainable cash flow expansion from 2024-2030[27] - L12M EBITDA per 3Q25 reached 2.6 BUSD, a +500 MUSD increase compared to 3Q24[135] - L12M Free cash flow per 3Q25 was 715 MUSD, a +592 MUSD increase compared to 3Q24[135] Market Dynamics and Strategy - Urea demand growth remains consistent, with total nitrogen showing a 1.1% trend growth and urea specifically at 1.7% trend growth[43] - Yara's European finished nitrogen products have >75% flexibility on ammonia source[22, 58, 91, 133, 178] - The company's AdBlue and TAN business has seen a ~160% increase in commercial EBITDA since 2019[97] - Yara's durian solutions in Thailand have led to a 45000 t of NPKs p.a at 40% premium[109] Production and Cost Efficiency - Yara achieved all-time high production volumes, resulting in a ~250 MUSD impact[62] - The company is actively managing its portfolio, with actions taken on all harvest sites resulting in >200 MUSD annual cash flow impact[68] - Yara has achieved >180 MUSD in fixed cost reduction, with a high drop-through impact on EBITDA[27, 168]

Attacking Bladder Cancer for a Better Tomorrow | 1 Disclaimer and Forward -Looking Statements We caution you that this presentation contains forward -looking statements about us and our industry. All statements other than s tatements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, rese arch and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned clinical ...

Q1 FY26 Financial Performance - Net sales increased by 1% to $154.4 million, compared to $153.5 million in Q1 FY25 [12] - Gross margin improved by 140 basis points to 56.2% [12] - Operating income decreased by 7% to $23.3 million [12] - Net income decreased by 8% to $17.5 million [12] - Diluted EPS decreased by 8% to $1.28 [12] Segment Performance - Americas segment sales increased by 4%, representing 47% of global net sales [14] - EIMEA segment sales increased by 2%, representing 38% of global net sales [20] - Asia-Pacific segment sales increased by 10%, representing 15% of global net sales [22] Growth and Strategy - The company is targeting long-term maintenance product sales growth with a CAGR target in the mid-to-high single digits [31] - The company is focused on four strategic battles: geographic expansion, premiumization, WD-40 Specialist growth, and digital commerce [34] FY26 Guidance - The company reaffirmed FY26 sales growth guidance between 5% and 9%, leading to net sales between $630 million and $655 million [53]

NYSE: GBX 1Q26 Earnings Slides & Supplemental Information InvestorRelations@gbrx.com www.gbrx.com Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements, including statements that are not purely statements of historical fact. The Greenbrier Companies, Inc. (the "Company," "we," "us" or "our") uses words, and variations of words, such as "backlog," "believe," "capacity," "commit," "continue," "drive," "estimate," "expect," "focus," "future," "gr ...

Earnings Call: Q1 - FY26 January 8, 2026 $0.03 Diluted EPS $18.4M Revenue 19% Adj. EBITDA Margin -3% Revenue Decline Current period Prior Year Comparison (1Q25) $0.13 Adj. Diluted EPS $18.9M Revenue $0.01 Diluted EPS 24% Adj. EBITDA Margin +31% $0.17 Revenue Growth Adj. Diluted EPS Trailing Twelve Months (TTM) Highlights ($3.20) Diluted EPS (1) $78.7M Revenue 27% Adj. EBITDA Margin +6% Revenue Growth Current period Prior Year Comparison (1Q25) $0.98 Adj. Diluted EPS $74.4M Revenue $0.40 Diluted EPS 29% Adj. ...

Phase 2 COACH Trial Topline Week 52 Data January 8, 2026 Treatment with TransCon CNP and TransCon hGH combination therapy is investigational. For investor communication only. Not for use in product promotion. Not for further distribution. Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding TransCon hGH's ability to complement TransCon CNP's ho ...